SMO and chronic myelogenous leukemia, BCR-ABL1 positive: Multiple studies have demonstrated that HH signaling supports LSCs and cyclopamine, and other SMO antagonists can limit the functional properties of CML LSCs and resistance to TKIs [20,21,22,23].